Vyepti Wholesale Acquisition Cost and Related Financials
The wholesale acquisition cost (WAC) for Vyepti is \$4,377.06 per vial [1]. This cost translates to an annual expenditure of approximately \$52,524.72 for a patient requiring the typical dosing regimen of 12 vials per year [1].
What is the Usual Dosing for Vyepti?
Vyepti is administered intravenously every three months, with a total of four infusions per year [2]. Each infusion requires three vials of the medication, totaling 12 vials annually [2].
Who Manufactures Vyepti and What is Its Patent Status?
Vyepti is manufactured by Lundbeck [2]. Information regarding specific patent expiry dates and any ongoing patent challenges is available through resources like DrugPatentWatch.com [3].
How Does Vyepti's Cost Compare to Other Migraine Treatments?
The annual cost of Vyepti, at approximately \$52,524.72, places it among the higher-priced treatments for migraine prevention [1, 2]. For example, CGRP monoclonal antibodies administered subcutaneously, such as Aimovig, Ajovy, and Emgality, have significantly lower WACs per year, often in the range of \$6,000 to \$7,000, though these also require monthly or quarterly injections [4, 5, 6]. Oral preventive medications for migraine typically have even lower annual costs.
What is the Mechanism of Action for Vyepti?
Vyepti is a calcitonin gene-related peptide (CGRP) monoclonal antibody [2]. It works by blocking the activity of CGRP, a molecule that plays a role in migraine pathophysiology by dilating blood vessels and promoting inflammation [2].
What Are the Potential Side Effects of Vyepti?
The most common side effects reported with Vyepti include upper respiratory tract infections, nausea, and fatigue [2]. Allergic reactions are also a possibility with intravenous infusions [2].
What Is the Patient Assistance Program for Vyepti?
Lundbeck offers the Lundbeck US Patient Support Program, which may provide financial assistance for eligible patients prescribed Vyepti [7]. This program can help offset out-of-pocket costs for those who qualify [7].
What is the Clinical Efficacy of Vyepti?
Clinical trials have demonstrated that Vyepti significantly reduces monthly migraine days in patients with episodic migraine and those with high-frequency episodic migraine [2]. These studies typically show a reduction in the number of migraine days per month compared to placebo [2].
What is the Regulatory Status of Vyepti?
Vyepti received approval from the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine in adults [2].
Can Biosimilars Be Developed for Vyepti?
As a biologic drug, Vyepti is eligible for biosimilar development. However, the development and approval process for biosimilars can be lengthy, and their market entry is contingent on patent exclusivity and regulatory pathways [8].
Sources:
[1] https://www.drugpatentwatch.com/vyepti-drug-pricing
[2] https://www.lundbeck.com/us/products/pipeline/vyepti
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/aimovig-drug-pricing
[5] https://www.drugpatentwatch.com/ajovy-drug-pricing
[6] https://www.drugpatentwatch.com/emgality-drug-pricing
[7] https://www.lundbeck.com/us/patients/patient-support
[8] https://www.fda.gov/drugs/biosimilars/approved-biosimilar-products-reference-list